The Effectiveness of Common Cannabis Products for Treatment of Nausea

Abstract

Goals: We measure for the first time how a wide range of cannabis products affect nausea intensity in actual time. Background: Even though the Cannabis plant has been used to treat nausea for millennia, few studies have measured real-time effects of common and commercially available cannabis-based products. Study: Using the Releaf App, 886 people completed 2220 cannabis self-administration sessions intended to treat nausea between June 6, 2016 and July 8, 2019. They recorded the characteristics of self-administered cannabis products and baseline symptom intensity levels before tracking real-time changes in the intensity of their nausea. Results: By 1 hour postconsumption, 96.4% of people had experienced symptom relief with an average symptom intensity reduction of −3.85 points on a 0 to 10 visual analog scale (SD=2.45, d=1.85, P<0.001). Symptom relief was statistically significant at 5 minutes and increased with time. Among product characteristics, flower and concentrates yielded the strongest, yet similar results; products labeled as Cannabis indica underperformed those labeled as Cannabis sativa or hybrid; and joints were associated with greater symptom relief than pipes or vaporizers. In sessions using flower, higher tetrahydrocannbinol and lower cannabidiol were generally associated with greater symptom relief (eg, within 5 min). Conclusions: The findings suggest that the vast majority of patients self-selecting into cannabis use for treatment of nausea likely experience relief within a relative short duration of time, but the level of antiemetic effect varies with the characteristics of the cannabis products consumed in vivo. Future research should focus on longer term symptom relief, including nausea-free intervals and dosing frequency; the risks of consumption of medical cannabis, especially among high-risk populations, such as pregnant women and children; and potential interactions between cannabis, conventional antiemetics, other medications, food, tobacco, alcohol, and street drugs among specific patient populations.

Exploring medical cannabis use in individuals with a traumatic brain injury

“…This is aligned with other studies evaluating reasons for medical cannabis use [12,63]. Some studies on medical cannabis patients still report smoking as a popular route of administration [46,64]. This may reflect differences in medical cannabis patients who are self-treating or under the care of a healthcare provider and highlights the importance of education on how to best utilize medical cannabis.…”

Antimicrobial, Probiotic, and Immunomodulatory Potential of Cannabis sativa Extract and Delivery Systems

“…Legend: 11-Lactobacillus acidophilus 4356, 12-Lactobacillus casei ATCC 393, 13-Lactobacillus plantarum ATCC 14917, 14-Lactobacillus brevis ATCC 8287, 15 Extract from cannabis exhibits antimicrobial properties against both potentially pathogenic microorganisms and probiotic microorganisms, which are beneficial for health. The addition of HP-β-CD stimulates the growth of both pathogenic and probiotic microorganisms.…”

“…It has anti-inflammatory, antioxidant, antibacterial, and neuroprotective effects [9,10]. Cannabinoids might be used in neuropathic pain, spasticity in multiple sclerosis, nausea, vomiting, cancer pain, and certain behavioral symptoms in dementia [11][12][13][14][15][16][17]. Additionally, cannabis use might be beneficial in patients with inflammatory bowel diseases, anxiety disorders, and sleep disorders [18][19][20][21].…”

Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care

“…Data from 866 people using the Releaf App give further support to the benefit of the botanical as an effective treatment for nausea. 40 The ReleafApp patient education and cannabis treatment management tool was created to track patient sessions and real-time cannabis use experiences to optimize the therapeutic effects of cannabis consumption while minimizing negative side effects. Releaf App users enter information on the product they intend to consume, including type of product; when applicable, combustion method; plant subspecies; and THC and CBD potency levels.…”